- Conditions: Cord Blood Transplant; Hematologic Malignancy; Inherited Metabolic Disease
Intervention: Drug: TXA127
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified March 2012 - Condition: Essential Hypertension
Interventions: Drug: XOMA 985; Drug: Amlodipine Besylate; Drug: Perindopril Erbumine
Sponsors: XOMA (US) LLC; XOMA (US) LLC
Recruiting - verified March 2012 - Condition: HIV
Interventions: Drug: Lisinopril; Drug: Placebo
Sponsors: University of California, San Francisco; University of California, San Francisco; American Foundation for AIDS Research
Recruiting - verified February 2012 - Condition: Endothelial Dysfunction
Intervention: Drug: Telmisartan
Sponsors: University of California, Los Angeles; University of California, Los Angeles; The Campbell Foundation
Not yet recruiting - verified April 2012 - Conditions: Preeclampsia; Pregnancy Induced Hypertension
Intervention: Drug: Irbesartan
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified May 2012 - Conditions: Stage 1 Hypertension; Stage 2 Hypertension
Interventions: Drug: Nebivolol and Valsartan 1; Drug: Nebivolol and Valsartan 2; Drug: Nebivolol and Valsartan 3; Drug: Nebivolol 1; Drug: Nebivolol 2; Drug: Valsartan 1; Drug: Valsartan 2; Drug: Placebo
Sponsors: Forest Laboratories; Forest Laboratories
Recruiting - verified March 2012 - Condition: Angiotensin-converting Enzyme (ACE) Inhibitor-associated Angioedema
Interventions: Drug: HOE-140; Other: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of California, San Diego; Massachusetts General Hospital; University of California, Los Angeles
Recruiting - verified April 2012 - Condition: Hypertension
Intervention: Drug: Lisinopril
Sponsors: Duke University; Duke University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified March 2012 - Conditions: Nephropathy; Sickle Cell Anemia
Intervention: Drug: Losartan
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified March 2012 - Condition: Hypertension
Interventions: Drug: Metoprolol succinate; Drug: Nebivolol; Procedure: Forearm blood flow; Procedure: Microneurography; Procedure: Rhythmic handgrip exercise; Procedure: Lower body negative pressure; Drug: Angiotensin II
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Forest Laboratories
Recruiting - verified April 2012 - Condition: Hypertension
Interventions: Drug: Para-aminohippuric Acid; Drug: Angiotensin II; Drug: Norepinephrine
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Hypertension; Metabolic Syndrome
Intervention: Drug: Aliskerin/Valsartan and Rampiril
Sponsors: University of Michigan Health System; University of Michigan Health System; Novartis Pharmaceuticals
Recruiting - verified September 2011 - Conditions: Hypertension; Insulin Resistance
Interventions: Drug: Para-aminohippuric Acid; Drug: Angiotensin II; Drug: Norepinephrine
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified May 2012 - Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention: Drug: Contrast Enhanced Ultrasonography
Sponsors: University of Virginia; University of Virginia
Recruiting - verified January 2012 - Condition: HIV-infection
Intervention: Drug: Angiotensin II Infusion
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: lisinopril; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Septic Shock
Intervention: Drug: Angiotensin II
Sponsors: George Washington University; George Washington University
Not yet recruiting - verified July 2011 - Condition: Impaired Glucose Tolerance
Intervention: Drug: Administration of Sildenafil or Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified April 2012 - Condition: ACE Inhibitor Induced Angioedema
Interventions: Drug: ecallantide; Drug: ecallantide; Drug: ecallantide; Drug: placebo
Sponsors: Dyax Corp.; Dyax Corp.
Recruiting - verified April 2012 - Conditions: Renal Function; Endothelial Function; Blood Pressure; Overweight; Obesity
Interventions: Drug: Vitamin D ergocalciferol; Drug: Probenecid; Drug: Allopurinol; Drug: Placebo; Drug: Placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012 - Conditions: Double Cord Blood Transplant; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Myelofibrosis; Acute Lymphoblastic Leukemia; Chronic Myelocytic Leukemia; Non Hodgkins Lymphoma; Hodgkins Lymphoma; Chronic Lymphocytic Leukemia
Intervention: Drug: TXA127
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified December 2011 - Conditions: Hypertension; Pure Autonomic Failure; Multiple System Atrophy
Interventions: Drug: Losartan; Drug: Captopril; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Conditions: Hypertension, Grade 1; Hypertension Treatment; N of 1 Study Design; Hypertension
Interventions: Drug: Lisinopril; Drug: Hydrochlorothiazide
Sponsors: Scripps Translational Science Institute; Scripps Translational Science Institute
Recruiting - verified January 2012 - Conditions: Hypertension; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: lisinopril; Drug: losartan potassium; Other: laboratory biomarker analysis; Drug: benazepril hydrochloride; Drug: ramipril
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Postural Tachycardia Syndrome
Interventions: Drug: Losartan; Drug: Ascorbic Acid (Vitamin C); Drug: Normal Saline
Sponsors: New York Medical College; New York Medical College
Recruiting - verified December 2011 - Condition: Hypertension
Interventions: Drug: Aliskiren; Drug: Enalapril
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular Dystrophy
Intervention: Drug: Coenzyme Q10 and Lisinopril
Sponsors: Cooperative International Neuromuscular Research Group; Cooperative International Neuromuscular Research Group; Department of Defense
Recruiting - verified November 2011 - Conditions: Lymphoma, Non-Hodgkin; Hodgkin Disease; Multiple Myeloma
Interventions: Drug: TXA127; Drug: Placebo
Sponsors: US Biotest, Inc.; US Biotest, Inc.; Tarix Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Metabolic Diseases; Diabetes Mellitus; Endocrine System Diseases; Glucose Metabolism Disorders
Interventions: Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation; Drug: Administration of Aliskiren, Spironolactone, or Placebo; Drug: Increased Dose, Combination, or Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified August 2011 - Condition: Type 2 Diabetes
Interventions: Drug: ACEI or ARB; Drug: Lisinopril
Sponsors: University of Virginia; University of Virginia
Recruiting - verified December 2011 - Conditions: Methamphetamine Dependence; Methamphetamine Abuse; Substance Abuse
Interventions: Drug: Perindopril; Drug: Placebo; Drug: Candesartan
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Condition: Angioedema
Intervention: Drug: ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Sponsors: Bernstein, Jonathan A., M.D.; Bernstein, Jonathan A., M.D.; Dyax Corp.
Recruiting - verified March 2012 - Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Schizophrenia; Schizoaffective Disorder
Interventions: Drug: Telmisartan; Drug: Placebo
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Acute Decompensated Heart Failure; Congestive Heart Failure
Interventions: Drug: Aliskiren; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: enalapril maleate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012 - Conditions: Oxidative Stress; Endothelial Dysfunction
Interventions: Drug: ramipril (ACE inhibitor); Drug: valsartan (ARB); Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University; University of Washington; National Institutes of Health (NIH)
Recruiting - verified January 2012 - Condition: Chronic Heart Failure
Interventions: Drug: Enalapril monotherapy; Drug: Aliskiren monotherapy; Drug: Aliskiren / Enalapril combination therapy
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Adalimumab; Drug: Lisinopril, losartan, and atorvastatin; Drug: galactose
Sponsors: New York University School of Medicine; New York University School of Medicine; University of Michigan; The Cleveland Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012 - Condition: Hypertension
Intervention: Drug: losartan potassium
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Intracerebral Hemorrhage; Stroke; Hypertension
Intervention: Other: Blood pressure management policies
Sponsors: The George Institute; The George Institute; National Health and Medical Research Council, Australia
Recruiting - verified February 2012 - Conditions: Hemodialysis; Hypertension; Left Ventricular Hypertrophy
Interventions: Drug: Lisinopril; Drug: Atenolol
Sponsors: Indiana University; Indiana University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Conditions: Kidney Disease; Nephropathy; Type 2 Diabetes
Interventions: Drug: losartan; Drug: lisinopril; Drug: losartan
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2012 - Condition: IgA Nephropathy
Interventions: Drug: Intravenous Rituximab; Drug: Group 2 ACE/ARB
Sponsors: Mayo Clinic; Mayo Clinic; Ohio State University; Stanford University; University of North Carolina, Chapel Hill; Columbia University
Recruiting - verified March 2012 - Conditions: Kidney Transplant; Kidney Transplantation; Renal Transplant
Interventions: Drug: ramipril; Drug: ramipril
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Hermansky-Pudlak Syndrome (HPS); Pulmonary Fibrosis; Oculocutaneous Albinism; Platelet Storage Pool Deficiency; Metabolic Disease
Interventions: Drug: Losartan; Drug: Zileuton; Drug: N-Acetylcysteine; Drug: Prevastatin; Drug: Erythromycin
Sponsors: National Institutes of Health Clinical Center (CC); National Human Genome Research Institute (NHGRI)
Recruiting - verified December 2010 - Condition: Hypertension
Interventions: Drug: Clonidine; Drug: Nitroglycerin transdermal; Drug: Dipyridamole/ Aspirin (Aggrenox); Drug: Desmopressin (DDAVP); Drug: Sildenafil; Drug: Nifedipine; Drug: Hydralazine; Drug: Hydrochlorothiazide; Drug: Placebo; Drug: Bosentan; Drug: Diltiazem; Drug: Eplerenone; Drug: guanfacine; Dietary Supplement: L-arginine; Drug: captopril; Drug: carbidopa; Drug: losartan; Drug: metoprolol tartrate; Drug: nebivolol hydrochloride; Drug: prazosin hydrochloride; Drug: tamsulosin hydrochloride; Other: Head-up tilt.
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
 |
Angiotensin Clinical Trials |
